Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer.
Adenocarcinoma
/ complications
Aged
Aged, 80 and over
Anorexia
/ diagnosis
Body Mass Index
Esophageal Neoplasms
/ complications
Esophagogastric Junction
/ pathology
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Nutrition Assessment
Quality of Life
Self Report
Stomach Neoplasms
/ complications
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
06
2019
accepted:
15
10
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Cancer cachexia is common in patients with oesophagogastric cancer (OG) and is linked to overall survival (OS). One of the key components of cachexia is anorexia; it is not known whether anorexia impacts on OS and there is no method of routine screening in current practice. Diagnosis relies on patients describing the symptoms, clinicians diagnosing anorexia and acting upon it. Patients with oesophageal/gastroesophageal junction or gastric cancer were assessed using the Functional Assessment of Anorexia Cachexia Therapy Anorexia/Cachexia Subscale (FAACT A/CS). FAACT A/CS includes 12 questions validated previously to diagnose anorexia in patients with cancer. Of the 182 patients included, 69% scored ≤37/48 and were considered to be anorexic; FAACT A/CS was a better predictor of OS in metastatic patients than body mass index or weight loss in the six months prior to cancer diagnosis. The median OS of patients with FAACT A/CS scores of >37 was longer than patients with scores of ≤37 (19.3 months vs 6.7 months, Hazard Ratio [HR] 2.9, 95% Confidence Interval [CI] 1.4-6.0, p<0.0001). Patients with performance status (PS) 0-2 and FAACT A/CS >37 had substantially longer OS than those with PS 0-2 and FAACT A/CS ≤37 (18.7 months vs 7.9 months, HR 2.5 (95% CI 1.2-5.1, P<0.0001). The FAACT A/CS questionnaire allows clinicians to identify patients with anorexia who may benefit from early nutrition interventions. Importantly, this is the first study to show the association between anorexia and survival in patients with metastatic OG cancers. This will form the basis of future interventional studies to improve patient outcomes.
Identifiants
pubmed: 31774822
doi: 10.1371/journal.pone.0224540
pii: PONE-D-19-14596
pmc: PMC6881015
doi:
Banques de données
figshare
['10.6084/m9.figshare.9293483.v1']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224540Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Gastric Cancer. 2019 Jan;22(1):10-22
pubmed: 30276574
Support Care Cancer. 2009 Feb;17(2):129-35
pubmed: 18386071
Ann Oncol. 2014 Aug;25(8):1492-9
pubmed: 24569913
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Gastric Cancer. 2016 Apr;19(2):597-606
pubmed: 25749718
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Cancer. 1988 May 15;61(10):2022-6
pubmed: 2452006
Support Care Cancer. 2016 Feb;24(2):661-666
pubmed: 26160463
J Am Med Dir Assoc. 2010 May;11(4):229-30
pubmed: 20439040
Dis Esophagus. 2018 Aug 1;31(8):
pubmed: 29846548
Oncotarget. 2017 Aug 10;8(45):79884-79896
pubmed: 29108370
J Clin Oncol. 2015 Jan 1;33(1):90-9
pubmed: 25422490
Crit Rev Oncol Hematol. 2011 Oct;80(1):114-44
pubmed: 21216616
BMJ Support Palliat Care. 2018 Sep;8(3):258-265
pubmed: 29440149
Qual Life Res. 2000;9(10):1137-46
pubmed: 11401046
PLoS One. 2014 Feb 28;9(2):e88553
pubmed: 24586342
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Dis Esophagus. 2017 Sep 1;30(9):1-7
pubmed: 28859366
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
Ann Oncol. 2014 Aug;25(8):1635-42
pubmed: 24562443
Eur J Cancer. 1998 Mar;34(4):503-9
pubmed: 9713300